Upstream / Downstream
Explore pathways related to this product.
CST Antibody Performance Guarantee
Find answers on our FAQs page.
- Additional protein information
- Analytical tools
Phospho-FLT3 Antibody Sampler Kit #12596
This product is discontinued
The Phospho-FLT3 Antibody Sampler Kit provides an economical means of evaluating the FLT3 tyrosine kinase and several phosphorylation sites that are involved in its activation. The kit includes enough antibody to perform four western blot experiments with each primary antibody.
The phospho-FLT3 antibodies recognize the phosphorylated form of FLT3 at the indicated sites. The Phospho-FLT3 (Tyr591) (33G6) Rabbit mAb and Phospho-FLT3 (Tyr969) (C24D9) Rabbit mAb may cross-react with other tyrosine-phosphorylated proteins. The Phospho-FLT3 (Tyr842) (10A8) Rabbit mAb may cross-react with other tyrosine phosphorylated family members. The control FLT3 antibody recognizes both the phosphorylated and nonphosphorylated forms of this kinase.
Monoclonal antibodies are produced by immunizing animals with synthetic phosphopeptides corresponding to residues surrounding Tyr589/591, Tyr591, Tyr842 or Tyr969 of human FLT3. The FLT3 antibody is produced by immunizing animals with a synthetic peptide surrounding Ser740 of human FLT3.
FMS-related tyrosine kinase 3 (FLT3, also called Flk2), is a member of the type III receptor tyrosine kinase family, which includes c-Kit, PDGFR and M-CSF receptors. FLT3 is expressed on early hematopoietic progenitor cells and supports growth and differentiation within the hematopoietic system (1,2). FLT3 is activated after binding with its ligand FL, which results in a cascade of tyrosine autophosphorylation and tyrosine phosphorylation of downstream targets (3). The p85 subunit of PI3 kinase, SHP2, GRB2 and Shc are associated with FLT3 after FL stimulation (4-6). Tyr589/591 is located in the juxtamembrane region of FLT3 and may play an important role in regulation of FLT3 tyrosine kinase activity. Somatic mutations of FLT3 consisting of internal tandem duplications (ITDs) occur in 20% of patients with acute myeloid leukemia (7).
For Research Use Only. Not For Use In Diagnostic Procedures. Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. U.S. Patent No. 5,675,063.